The costs and expenses are worth it if they allow the company to be properly valued. Clearly Australians don't know how to value biotech. OCC has FDA and EU approvals, a global distribution cash deal with the world leader in dental products, but it is valued less than before it achieved these milestones. It's absurd.
The costs and expenses are worth it if they allow the company to...
-
- There are more pages in this discussion • 472 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.5¢ |
Change
-0.005(1.16%) |
Mkt cap ! $89.07M | |||
| Open | High | Low | Value | Volume |
| 43.0¢ | 43.0¢ | 42.0¢ | $90.9K | 214.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 12850 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 24056 | 2 |
View Market Depth
| Last trade - 15.54pm 27/09/2024 (20 minute delay) ? |
| OCC (ASX) Chart |